<DOC>
	<DOCNO>NCT01159587</DOCNO>
	<brief_summary>The project control observational , multicenter , prospective data collection secondary prophylaxis Kogenate Bayer adolescent adult severe haemophilia A ( FVIII &lt; 1 % ) . The observational period cover least 5 year per patient . The long-term secondary prophylaxis group compare versus on-demand treatment group assessment orthopedic status progression pharmacoeconomics evaluation .</brief_summary>
	<brief_title>Prophylaxis Versus On-demand Therapy Through Economic Report</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>age ≥ 12 year ≤ 55 year severe haemophilia A ( FVIII &lt; 1 % ) absence inhibitor ( Bethesda titre &lt; 0.6 BU/ml ) Previous Treated Patients ( prior exposure day &gt; 200 ) Kogenate Bayer administer 2030 IU/kg 3 time week , prophylaxis group ≥ 6 joint bleeds require treatment FVIII concentrate previous 6 month enrollment , ondemand group write informed consent concomitant severe chronic disease congenital skeletal malformation unreliability patient likelihood followup failure presence inhibitor history inhibitor ( previous 2 year ) currently immune tolerance treatment hepatic cirrhosis liver disease rapid progression AIDS platelet count &lt; 75,000/mm3 presence condition influence negatively patient´s compliance participation another study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>